NLS Pharmaceutics Ltd.
General Information | |
Business: |
We are an innovative biopharmaceutical company engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders, including narcolepsy and ADHD (Attention Deficit Hyperactivity Disorder). CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders. (Note: This is a unit offering.) |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 4 |
Founded: | 2015 |
Contact Information | |
Address | Alter Postplatz 2, CH-6370 Stans, Switzerland |
Phone Number | +41.79.779.60.00 |
Web Address | |
View Prospectus: | NLS Pharmaceutics Ltd. |
Financial Information | |
Market Cap | |
Revenues | $0 mil (last 12 months) |
Net Income | $-6.5 mil (last 12 months) |
IPO Profile | |
Symbol | NLSP |
Exchange | NASDAQ |
Shares (millions): | 3.6 |
Price range | $5.00 - $6.00 |
Est. $ Volume | $20.0 mil |
Manager / Joint Managers | Maxim Group LLC |
CO-Managers | Brookline Capital (A division of Arcadia Securities) |
Expected To Trade: | |
Status: | TBA |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |